2024.11.12 -

Caliway Announced EMA Orphan Drug Designation Granted to CBL-514 for Dercum’s Disease Treatment

CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum’s disease treatment.

2024.10.23 -

Caliway Completed CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction

The first and only lipolytic injectable for large area – CBL-514’s last Phase 2b study has been completed

2024.10.02 -

Caliway Successfully Lists on Taipei Exchange Following IPO

Caliway is pleased to announce the successful completion of its initial public offering (IPO) and up-listing from the Emerging Stock Market to the Taipei Exchange (TWSE-6919).

2024.08.26 -

Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease

Caliway announced that the subject recruitment of CBL-514 Phase 2b study for Dercum’s disease has been initiated. The study results are anticipated in Q4 2025.

Caliway Completed CBL-514 Phase 2b Study for Subcutaneous Fat Reduction with Topline Result Expected in Q4 2024

Caliway announces that the CBL-0204 Phase 2b study was completed successfully at the end of May. The topline results are anticipated in Q4 2024.

Caliway Presents CBL-514 Phase 2 Subcutaneous Fat Reduction Study Results Met All the Endpoints Successfully at AMWC Asia-TDAC 2024

Caliway is pleased to announce that Dr. Peter Peng, Chair of the Taiwan Society for Dermatology and Aesthetic Surgery, presents the results of the Phase II clinical trial of CBL-514, the first-in-class candidate drug developed by Caliway, for localized fat reduction at the AMWC Asia-TDAC 2024.

2024.05.12 -

Caliway Completes the Subject Recruitment in CBL-514 Phase 2b Study for Subcutaneous Fat Reduction

Caliway announces the completion of subject recruitment in the CBL-0205 Phase 2b study, enrolling a total of 173 subjects.

2024.05.11 -

Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention

Caliway is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT.